ReviR Therapeutics Gains FDA Orphan Drug Designation for RTX-117 as a Treatment for Charcot-Marie-Tooth Disease ReviR Therapeutics has received FDA Orphan Drug Designation for RTX-117, aimed at treating Charcot-Marie-Tooth Disease and addressing critical medical needs.

ReviR Therapeutics Gains FDA Orphan Drug Designation for RTX-117 as a Treatment for Charcot-Marie-Tooth Disease #United_States #ReviR_Therapeutics #Brisbane #CMT_disease #RTX-117

Cure CMT: Pioneering Efforts for Charcot-Marie-Tooth Patients with Innovative Medical Solutions Cure CMT is a newly launched nonprofit dedicated to providing braces and surgeries for patients with Charcot-Marie-Tooth disease, paving the way for a brighter future.

Cure CMT: Pioneering Efforts for Charcot-Marie-Tooth Patients with Innovative Medical Solutions #USA #Chicago #Patient_Care #CMT_disease #Cure_CMT